Research powered investment banking
Home
Research
Companies
Themes
Top Picks
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
Posts
Investor Scoring
sign in
Member sign in
Join redeye
Home
research
Companies
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
community
Posts
Investor Scoring
The latest from Redeye about Scandinavian Life Science and Technology companies
IDL Biotech
Showing progression in line with investment case
Speqta
Videointervju med vd Andereas Friis
Targovax
A breath of optimism in the Q2 reporting
Stillfront Group
Level up through live ops
Clemondo Group
Prickar vår resultatprognos
Smart Eye
Q2'19: Slightly faster license growth - losses according to plan
Heliospectra
Q2’19: First comment
Railcare Group
På rätt spår
Hexatronic Group
Rest of Europe is now Hexatronic’s largest market
Xbrane Biopharma
Marginell försening i rekryteringen, påverkar inte vår syn
Image Systems
Mixed bag
Xvivo Perfusion
Lung Bioengineering to use XPS in new center
Catella
Kanonresultat!
Cantargia
Ännu ett händelserikt kvartal i ryggen
Events
28
Aug
Cancer Imaging Lunch
29
Aug
Investor Lunch
05
Sep
Investor After Work Göteborg
06
Sep
Mycronic: Investor Lunch
10
Sep
Online Gambling Malta (English)
10
Sep
Investor Lunch
Announcements
New accounting principle to affect upcoming interim reports
Redeye söker Projektledare inom Corporate Finance
Redeye sponsrar integrationsprojektet Näringslivet Möter Förorten